THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, February 24, 2021
Arctoris celebrates its 5th anniversary with the unveiling of a new and expanded, next-generation robotic platform, which plays a central catalytic role in drug discovery.
FREMONT, CA: Arctoris, an Oxford-based technology firm operating a fully automated drug discovery platform, celebrated its 5th anniversary on the 4th of February. Over the past few years, Arctoris has evolved from a technology startup to a pioneering operating company offering integrated drug discovery projects with partners from its headquarters in Oxford and its Asia-Pacific hub in Singapore. On its 5th anniversary, Arctoris launches it is new and widened, next-generation robotic platform, Ulysses.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Arctoris founded by Martin-Immanuel Bittner MD DPhil (CEO) and Tom Fleming MChem, the world’s first fully automated drug discovery platform. Through automation, the firm’s unique technology platform quickly offers reliable, reproducible, and fully auditable datasets allowing better decision-making early in the drug discovery process.
The drug discovery ecosystem is evolving quickly, and the key to success is having access to the right data at the right time to progress the right projects towards the clinic. Arctoris plays a vital role in allowing true data-driven drug discovery globally by creating the data that powers decisions in biotech and pharma firms on three continents.
Drug discovery is undergoing a quick digital metamorphosis, and Ulysses plays a catalytic role in that transformation. This success results from the amazing teams' dedication and hard work over these past five years, coupled with guidance from experienced and insightful advisors and board members. The company is looking forward to the next five years, which will see even significant change and accelerated growth, toward a future where treatments and cures can be created at a fraction of the time and cost. The company is privileged to play its role in developing that future.
Having strengthened its team with several high-profile hires and Advisory Board appointments, the firm has announced partnerships with Insilico Medicine and Syntekabio while further widening its operations globally. The founders set out with the concept to make it possible for any scientist in the world to run a biotech firm with a laptop and a credit card - and this is now entirely possible, using the power of automation for drug discovery.
More in News